ERBB2 and breast carcinoma: BM developed from a significant proportion of breast cancer is reported to overexpress EGFR‐2 (HER2/neu)[169] or from triple‐negative breast cancer (TNBC) expressing EGFR‐1.[170] To enable precise targeted BM treatment, Patil et al.